SCHEMBL7239408

SCHEMBL7239408

COc1cc(Cl)cc(C(=O)N(C(C)C)C(C)C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDR1 Q08345 1/20 0.41
▸ NPSR1 Q6W5P4 4/20 0.39
▸ HPGD P15428 4/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ MCOLN3 Q8TDD5 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ FFAR2 O15552 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ LTB4R Q15722 1/20 0.37
▸ SLC6A2 P23975 1/20 0.36
▸ SLC6A4 P31645 1/20 0.36
▸ SLC6A3 Q01959 1/20 0.36
▸ S1PR3 Q99500 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ BCL2L1 Q07817 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7395932 0.83 KMT2A (0.38) HPGDKMT2AMEN1ALDH1A1POLB
SCHEMBL6961808 0.79 HSD17B10 (0.43) DDR1NPSR1HPGDKMT2AMEN1
SCHEMBL7239319 0.78 HCAR1 (0.53) NPSR1HPGDKMT2AALDH1A1MCOLN3
SCHEMBL6970185 0.78 F2 (0.43) DDR1NPSR1HPGDKMT2AMEN1
SCHEMBL6975927 0.76 HSD17B10 (0.41) DDR1NPSR1HPGDKMT2AMEN1
SCHEMBL1188720 0.75 TPMT (0.61) DDR1HPGDFFAR2KDM4E
SCHEMBL1188363 0.75 LMNA (0.47) DDR1HPGDKMT2AMEN1ALDH1A1
SCHEMBL986399 0.75 HPGD (0.44) DDR1HPGDPOLBFFAR2KDM4E
SCHEMBL30251625 0.75 TPMT (0.61) DDR1HPGDFFAR2KDM4E
SCHEMBL12989210 0.75 CES2 (0.61) KMT2AMEN1SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6670381-B2 (pyridin-4-ylamino)-alkoxy)-benzamide derivatives SMITHKLINE BEECHAM CORPORATION 2003-12-30 — — US disclosed
US-20020169189-A1 Benzamide derivatives as thrombin inhibitors KELLY HENRY ANDERSON (GB) 2002-11-14 — — US disclosed
US-6441008-B1 ANTICOAGULANTS SMITHKLINE BEECHAM CORPORATION 2002-08-27 — — US disclosed
EP-1117644-A1 BENZAMIDE DERIVATIVES AS THROMBIN INHIBITORS GLAXO GROUP LIMITED (GB) 2001-07-25 — — EP disclosed
WO-2000020394-A1 BENZAMIDE DERIVATIVES AS THROMBIN INHIBITORS GLAXO GROUP LIMITED (GB) 2000-04-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169189-A1 Benzamide derivatives as thrombin inhibitors TFPI, TFPI2, F3 DDR1 1301/4885NPSR1 1416/4885HPGD 3213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback